US FTC withdraws remaining antitrust claim against AbbVie
MLex Summary: Following a decision by the US Supreme Court not to review the Federal Trade Commission’s antitrust case against AbbVie over AndroGel, the FTC has withdrawn its remaining count in...To view the full article, register now.
Already a subscriber? Click here to view full article